Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 86

Sort by

Sort Order Select

Journal Articles

Adult Langerhans Cell Histiocytosis with Liver Involvement

Long Chang, Lin He, Huacong Cai, Minghui Duan, Jian Li, Daobin Zhou, Gaurav Goyal, Xinxin Cao

Blood (2023) 142 (Supplement 1): 3197.

https://doi.org/10.1182/blood-2023-184790

Published: 2023

Journal Articles

Recommendations on Minimal Residual Disease Monitoring in Acute Promyelocytic Leukemia Treated with Combination of All- Trans Retinoic Acid and Arsenic Trioxide

Blood (2023) 142 (Supplement 1): 2946.

https://doi.org/10.1182/blood-2023-184433

Published: 2023

Journal Articles

Ixazomib Maintenance Therapy in Chinese Patients with Newly Diagnosed Multiple Myeloma Not Treated with Stem Cell Transplantation: A Single-Arm, Open-Label Study

Weijun Fu, Juan Du, Lu Zhong, Lijuan Chen, Jian Li, Donghua Zhang, Jianqing Mi, Yan Liu, Sheng Wu, Richard Labotka, Cong Li, Wenhan Jiang, Wenming Chen

Blood (2023) 142 (Supplement 1): 6735.

https://doi.org/10.1182/blood-2023-181444

Published: 2023

Journal Articles

Childhood AML Combined with AML1-ETO Fusion Gene and c-KIT or Other Mutations Had Favorable Survival Treated By the C-Huanan AML 2015 Protocol: Study in Multicenter of South of China

Xiaoqin Feng, Chunfu Li, Jian Li, Yongzhi Zheng, Mincui Zheng, Huirong Mai, Lihua Yang, Xiangling He, Yingyi He, Hong Wen, Yirong Li

Blood (2023) 142 (Supplement 1): 4291.

https://doi.org/10.1182/blood-2023-186587

Published: 2023

Journal Articles

Renal Response of Selinexor, Pomalidomide, Bortezomib and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients with Renal Impairment: A Prospective, Open-Label, Multicenter, Phase 2 Study

Blood (2023) 142 (Supplement 1): 4754.

https://doi.org/10.1182/blood-2023-180736

Published: 2023

Journal Articles

Pirtobrutinib in Post-cBTKi CLL/SLL: ~30 Months Follow-up and Subgroup Analysis With/Without Prior BCL2i from the Phase 1/2 BRUIN Study

Blood (2023) 142 (Supplement 1): 325.

https://doi.org/10.1182/blood-2023-185852

Published: 2023

Journal Articles

Impact of Long-Term Treatment with Belantamab Mafodotin on Safety and Efficacy Outcomes in Patients with Relapsed/Refractory Multiple Myeloma in DREAMM-3

Blood (2023) 142 (Supplement 1): 3357.

https://doi.org/10.1182/blood-2023-178009

Published: 2023

Journal Articles

Clinical Characteristics, Genomic Profiling and Outcomes of Langerhans Cell Histiocytosis in Adults with Single System Multifocal Disease

Hong-Xiao Han, Long Chang, Min Lang, Lin He, Jian Li, Minghui Duan, Daobin Zhou, Xinxin Cao, Wen Gao

Blood (2023) 142 (Supplement 1): 1165.

https://doi.org/10.1182/blood-2023-178177

Published: 2023

Journal Articles

A Conditioning Regimen of Bendamustine and Melphalan for Autologous Stem Cell Transplantation in Multiple Myeloma: A Phase 2, Single-Arm, Prospective Study

Qiang Zeng, Jian Li, Tian Dong, Xinchuan Chen, Pu Kuang, Ting Niu, Jie Ji, Zhigang Liu, Ting Liu

Blood (2023) 142 (Supplement 1): 7066.

https://doi.org/10.1182/blood-2023-174304

Published: 2023

Journal Articles

Lenalidomide and Dexamethasone for Patients with Rosai-Dorfman Disease: A Single Arm, Single Center, Prospective Phase 2 Study

Long Chang, Lin He, Jian Li, Daobin Zhou, Xinxin Cao, Wen Gao

Blood (2023) 142 (Supplement 1): 6331.

https://doi.org/10.1182/blood-2023-184621

Published: 2023

Journal Articles

A phase 2 prospective study of bortezomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed iMCD

Hao Zhao, Miao-yan Zhang, Kai-ni Shen, Jun Feng, Xin-xin Cao, Ming-hui Duan, Dao-bin Zhou, Lu Zhang, Jian Li

Blood (2023) 141 (21): 2654–2657.

https://doi.org/10.1182/blood.2023020009

Published: 2023

Includes: Supplemental data

Journal Articles

Single-Cell Transcriptome Analysis Reveals Stem Cell-like Subsets in the Progression of Waldenström's Macroglobulinemia

Yu Qiu, Xiaoshuang Wang, Yuan Yao, Yanmin Si, Xuezhu Wang, Mingnan Jia, Daobin Zhou, Jia Yu, Jian Li, Xin-xin Cao

Blood (2022) 140 (Supplement 1): 6385–6386.

https://doi.org/10.1182/blood-2022-156435

Published: 2022

Journal Articles

Impact of Dialysis Dependence on Survival for Multiple Myeloma Patients with Renal Impairment: A Multicenter Retrospective Study in China

Yuan Jian, Huixing Zhou, Weiwei Xie, Yuan Ren, Zhiyao Zhang, Guangzhong Yang, Chuanying Geng, Jing Jia, Wenming Chen, Jian Li, Wenrong Huang, Xinan Cen, Wen Gao

Blood (2022) 140 (Supplement 1): 12635–12636.

https://doi.org/10.1182/blood-2022-159950

Published: 2022

Journal Articles

High Mutational Burden of Chromatin-Modifying Genes Defines a Relatively Indolent Subgroup of Plasma Cell Dyscrasias

Xuezhu Wang, Bing Qiao, Yanying Yu, Jian Xu, Liping Zuo, Jia Chen, Hao Cai, Hong-xiao Han, Xin-xin Cao, Chunyan Sun, Jian Li

Blood (2022) 140 (Supplement 1): 12452–12453.

https://doi.org/10.1182/blood-2022-164477

Published: 2022

Journal Articles

Efficacy and Safety of Peginterferon Alfa-2b in 95 Patients with Myeloproliferative Neoplasms:a Single Center Retrospective Analysis

Long Chang, Hao Cai, Xinxin Cao, Jian Li, Daobin Zhou, Minghui Duan

Blood (2022) 140 (Supplement 1): 12244.

https://doi.org/10.1182/blood-2022-168360

Published: 2022

Journal Articles

Oligosecretory Waldenström Macroglobulinemia Patients Exhibit Excellent Treatment Response and Outcomes

Blood (2022) 140 (Supplement 1): 9289–9291.

https://doi.org/10.1182/blood-2022-157311

Published: 2022

Journal Articles

Phase I Study of a BCMA-Directed CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma Manufactured in <3 Days Using the High-Performance Platform

Hui Liu, Ting Wang, Yazi Yang, Ru Feng, Jiangtao Li, Chunli Zhang, Jiefei Bai, Yanping Ding, Guanghua Liu, Fei Wu, Xinan Lu, Jian Li, Ting He

Blood (2022) 140 (Supplement 1): 10307–10308.

https://doi.org/10.1182/blood-2022-166011

Published: 2022

Journal Articles

Renal Response of Pomalidomide with Bortezomib and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients with Renal Impairment: A Prospective, Open-Label, Multicenter, Phase 2 Study

Blood (2022) 140 (Supplement 1): 10167–10169.

https://doi.org/10.1182/blood-2022-159361

Published: 2022

Journal Articles

Rituximab and Bortezomib for Patients with Newly Diagnosed Acquired Haemophilia: Single Arm, Single Center, Prospective Phase 2 Study

Huacong Cai, Xinxin Cao, Shujie Wang, Yongqiang Zhao, Jian Li, Tie-nan Zhu

Blood (2022) 140 (Supplement 1): 2715–2716.

https://doi.org/10.1182/blood-2022-166513

Published: 2022

Journal Articles

LRG1, a Novel Serum Biomarker for Idiopathic Multicentric Castleman Disease Activity

Miaoyan Zhang, Yan-Ying Yu, Xin-xin Cao, Dao-Bin Zhou, Jian Li, Lu Zhang

Blood (2022) 140 (Supplement 1): 11923–11924.

https://doi.org/10.1182/blood-2022-156572

Published: 2022

NARROW

Adult Langerhans Cell Histiocytosis with Liver Involvement

Recommendations on Minimal Residual Disease Monitoring in Acute Promyelocytic Leukemia Treated with Combination of All- Trans Retinoic Acid and Arsenic Trioxide

Ixazomib Maintenance Therapy in Chinese Patients with Newly Diagnosed Multiple Myeloma Not Treated with Stem Cell Transplantation: A Single-Arm, Open-Label Study

Childhood AML Combined with AML1-ETO Fusion Gene and c-KIT or Other Mutations Had Favorable Survival Treated By the C-Huanan AML 2015 Protocol: Study in Multicenter of South of China

Renal Response of Selinexor, Pomalidomide, Bortezomib and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients with Renal Impairment: A Prospective, Open-Label, Multicenter, Phase 2 Study

Pirtobrutinib in Post-cBTKi CLL/SLL: ~30 Months Follow-up and Subgroup Analysis With/Without Prior BCL2i from the Phase 1/2 BRUIN Study

Impact of Long-Term Treatment with Belantamab Mafodotin on Safety and Efficacy Outcomes in Patients with Relapsed/Refractory Multiple Myeloma in DREAMM-3

Clinical Characteristics, Genomic Profiling and Outcomes of Langerhans Cell Histiocytosis in Adults with Single System Multifocal Disease

A Conditioning Regimen of Bendamustine and Melphalan for Autologous Stem Cell Transplantation in Multiple Myeloma: A Phase 2, Single-Arm, Prospective Study

Lenalidomide and Dexamethasone for Patients with Rosai-Dorfman Disease: A Single Arm, Single Center, Prospective Phase 2 Study

A phase 2 prospective study of bortezomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed iMCD

Single-Cell Transcriptome Analysis Reveals Stem Cell-like Subsets in the Progression of Waldenström's Macroglobulinemia

Impact of Dialysis Dependence on Survival for Multiple Myeloma Patients with Renal Impairment: A Multicenter Retrospective Study in China

High Mutational Burden of Chromatin-Modifying Genes Defines a Relatively Indolent Subgroup of Plasma Cell Dyscrasias

Efficacy and Safety of Peginterferon Alfa-2b in 95 Patients with Myeloproliferative Neoplasms:a Single Center Retrospective Analysis

Oligosecretory Waldenström Macroglobulinemia Patients Exhibit Excellent Treatment Response and Outcomes

Phase I Study of a BCMA-Directed CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma Manufactured in <3 Days Using the High-Performance Platform

Renal Response of Pomalidomide with Bortezomib and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients with Renal Impairment: A Prospective, Open-Label, Multicenter, Phase 2 Study

Rituximab and Bortezomib for Patients with Newly Diagnosed Acquired Haemophilia: Single Arm, Single Center, Prospective Phase 2 Study

LRG1, a Novel Serum Biomarker for Idiopathic Multicentric Castleman Disease Activity

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only